A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Clinical trial NCT01454934 · COMPLETED

Trial details

NCT number: NCT01454934
Sponsor: Eisai Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer (NSCLC)

Start date: 2011-12-09
Primary completion: 2014-05-30
Enrollment: 540

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.